---
title: "Revvity, Inc. (RVTY.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/RVTY.US.md"
symbol: "RVTY.US"
name: "Revvity, Inc."
industry: "Life Sciences Tools and Services"
---

# Revvity, Inc. (RVTY.US)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | US Market |
| Website | [www.revvity.com](https://www.revvity.com) |

## Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:13.000Z

**Overall: C (0.50)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 18 / 62 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.67% |  |
| Net Profit YoY | -10.79% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.57 |  |
| Dividend Ratio | 0.28% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11.37B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.86B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.22% | C |
| Profit Margin | 8.45% | B |
| Gross Margin | 54.77% | B |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.67% | C |
| Net Profit YoY | -10.79% | D |
| Total Assets YoY | -1.81% | D |
| Net Assets YoY | -5.43% | D |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1184.10% | B |
| OCF YoY | 3.67% | C |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.23 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 40.42% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Revvity, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.22%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "8.45%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "54.77%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.67%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.79%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.81%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.43%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1184.10%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "3.67%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.23",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "40.42%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A |
| 02 | Agilent Tech (US.A) | A | C | B | C | C | B |
| 03 | Waters (US.WAT) | A | B | B | C | C | B |
| 04 | WuXi Biologics (US.WXXWY) | B | B | D | A | B | B |
| 05 | West Pharmaceutical (US.WST) | B | B | B | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 47.16 | 18/59 | 48.33 | 41.63 | 37.22 |
| PB | 1.57 | 22/59 | 1.60 | 1.48 | 1.40 |
| PS (TTM) | 3.98 | 31/59 | 4.28 | 4.00 | 3.78 |
| Dividend Yield | 0.28% | 11/59 | 0.31% | 0.29% | 0.27% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T05:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 8 | 42% |
| Overweight | 3 | 16% |
| Hold | 8 | 42% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 100.33 |
| Highest Target | 140.00 |
| Lowest Target | 100.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/RVTY.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/RVTY.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/RVTY.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.